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Background: The free fatty acid receptors (FFAs), including FFA1 (orphan name: GPR40), FFA2 (GPR43) and FFA3
(GPR41) are G protein-coupled receptors (GPCRs) involved in energy and metabolic homeostasis. Understanding the
structural basis of ligand binding at FFAs is an essential step toward designing potent and selective small molecule
modulators.
Results: We analyse earlier homology models of FFAs in light of the newly published FFA1 crystal structure
co-crystallized with TAK-875, an ago-allosteric ligand, focusing on the architecture of the extracellular binding cavity
and agonist-receptor interactions. The previous low-resolution homology models of FFAs were helpful in highlighting
the location of the ligand binding site and the key residues for ligand anchoring. However, homology models were not
accurate in establishing the nature of all ligand-receptor contacts and the precise ligand-binding mode. From analysis
of structural models and mutagenesis, it appears that the position of helices 3, 4 and 5 is crucial in ligand docking. The
FFA1-based homology models of FFA2 and FFA3 were constructed and used to compare the FFA subtypes. From
docking studies we propose an alternative binding mode for orthosteric agonists at FFA1 and FFA2, involving the
interhelical space between helices 4 and 5. This binding mode can explain mutagenesis results for residues at
positions 4.56 and 5.42. The novel FFAs structural models highlight higher aromaticity of the FFA2 binding cavity
and higher hydrophilicity of the FFA3 binding cavity. The role of the residues at the second extracellular loop
used in mutagenesis is reanalysed. The third positively-charged residue in the binding cavity of FFAs, located in
helix 2, is identified and predicted to coordinate allosteric modulators.
Conclusions: The novel structural models of FFAs provide information on specific modes of ligand binding at
FFA subtypes and new suggestions for mutagenesis and ligand modification, guiding the development of
novel orthosteric and allosteric chemical probes to validate the importance of FFAs in metabolic and inflammatory
conditions. Using our FFA homology modelling experience, a strategy to model a GPCR, which is phylogenetically
distant from GPCRs with the available crystal structures, is discussed.Background
The free fatty acid receptors (FFAs) belong to Group A
of the G protein-coupled receptor (GPCR) family and
are activated endogenously by free fatty acids of different
chain lengths with varying levels of specificity [1]. The
free fatty acid receptor 1 (FFA1), previously known as
GPR40, has a preference to bind the long-chain fatty
acids with more than 12 carbon atoms [2, 3]. The free
fatty acid receptor 2 (FFA2), previously known as GPR43,
and the free fatty acid receptor 3 (FFA3), known as
GPR41, respond to short-chain fatty acids that have less* Correspondence: i.tikhonova@qub.ac.uk
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quence identity.
The recent discovery of FFAs involvement in glucose
and lipid homeostasis, adiposity and inflammation has
raised great interest to find small molecule ligands
modulating the function of these receptors and probe
them in the treatment of various metabolic and inflam-
matory conditions including obesity, type 2 diabetes,
atherosclerosis, cardiovascular diseases, ulcerative colitis,
Crohn’s disease and irritable bowel disease [5–8].
Several FFA1 agonists including GW9508, TAK-875/fasi-
glifam, AMG-837, AM1638, AM8182 (Fig. 1), LY2881835,
JTT-851 and P11187 were developed by industry using
high-throughput screening and subsequent medicinalhis article is distributed under the terms of the Creative Commons Attribution
ons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Agonists of the free fatty acid 1–3 receptors. The potency of compounds was taken from ref. 5, 9 and 13
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ical trials but removed due to toxicity [9]. Small select-
ive FFA2/FFA3 carboxylic acids derived from the
endogenous fatty acids (Fig. 1) have been developed as
FFA2/FFA3 agonists by academia, though with poor po-
tency [10]. A series of synthetic agonists has been pat-
ented by Euroscreen with potency up to 13nM [11].
AMG7703, also referred to as 4-CMTB, is a FFA2 se-
lective allosteric agonist (Fig. 1) that was discovered by
Amgen to inhibit lipolysis [12], yet, unfavourable phar-
macokinetic properties of AMG7703 prevented this
compound from progressing to clinical trials [12]. No
highly potent orthosteric agonists have been developed
at FFA3 to date. A series of FFA3 selective molecules,
for example 2 (Fig. 1) was reported by Arena Pharma-
ceuticals to act as positive or negative allosteric modu-
lators [9]. It is evident that a few available ligands of
FFAs have various limitations for clinical tests and the
development of novel FFA ligands presenting drug-like
properties is an emerging challenge to validate the role
of FFAs modulation in the therapy of metabolic and
immune disorders.
Understanding the structural basis of ligand binding at
FFAs would benefit discovery of potent and selective small
molecule modulators. Until recently, homology modellingin conjunction with mutagenesis has been used in
non-direct identification of ligand interactions in FFAs
[13, 14]. The structure-based approach using the vali-
dated FFA1 homology model together with ligand-
based approaches have been probed in in silico search
of orthosteric binders [15]. However, the crystal struc-
ture of FFA1 in complex with the ago-allosteric ligand,
TAK-875 has been recently published [16], providing
the first direct information of ligand binding at FFA1.
In this work we first compare previous homology
models of FFA1 [13, 14, 17] with the FFA1 crystallo-
graphic structure and use the experimental structure
for docking of orthosteric and allosteric agonists to fur-
ther delineate the agonist binding mode at FFA1. We
next use the FFA1 structure to build novel homology
models of FFA2 and FFA3 and compare the agonist
binding site of the receptor subtypes. Throughout the
study we link novel structural models of FFAs with
available mutagenesis and structure-activity relation-
ships (SAR) data. Our work extends the application of
the recent FFA1 crystal structure, further predicts agonist
binding regions at FFAs and suggests amino acid residues
for mutagenesis to verify their role in binding of orthos-
teric and allosteric agonists. Our work provides general
suggestions in modelling of distantly related GPCRs.
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Free fatty acid receptor 1
Structural models
We evaluate the earlier homology models of FFA1 built
by Tikhonova et al. [13, 15] and Sum, et al. [14, 17]
based on rhodopsin and β2 adrenergic (β2) receptor crys-
tal structures, templates with 16 % sequence identity to
model the ligand binding site with the FFA1 crystal
structure. In addition, the homology model based on the
protease-activated receptor 1 (PAR1) crystal structure
[18], the available template with the highest sequence
identity, 26 % is constructed and included to the ana-
lysis. The backbone superimposition of helices of the
crystal structure and homology models is shown in Fig. 2.
The root-mean-square deviation (RMSD) value for the
helix backbone is 2.8 Å for the rhodopsin-based and 1.9
Å for β2- and PAR1 -based FFA1 homology models. In
the upper side of the helical bundle forming the ligand
binding site a significant deviation is observed for helices
3, 4 and 5 with a backbone RMSD of 2–3.4 Å.
The earlier FFA1 homology models and mutagenesis
[13, 14, 17, 19] have predicted that an agonist binding
site is located between helices 3, 4, 5, 6 and 7, involv-
ing aY913.37, H1374.56, R1835.39, L1865.42, Y2406.51,
N2446.55 and R2587.35 [13, 14] (Fig. 2). The positionFig. 2 The superimposition of the FFA1 crystal structure and homology mode
structure, rhodopsin, β2 adrenergic and PAR1-based homology models are in y
important for ligand coordination based on mutagenesis and residue K
ligands are shown in stick-like representation. The green arrows indicat
structure compared to the homology modelsand orientation of Y2406.51, N2446.55 and R2587.35 are
similar between modelled and crystal structures with
a RMSD approaching 1.6 Å. In contrast, the RMSD
of Y913.37, H1374.56, R1835.39 and L1865.42 has a larger
value of 2–4 Å. In the homology models, Y913.37 is more
pointed toward helices 4 and 5, whereas it faces helix 6
forming interactions with Y2406.51 in the crystal structure.
We noted that helix 3 in FFA1 has a proline kink at pos-
ition 3.35 causing a slightly outward position of the helix
in the crystal structure, which appears to create space for
Y913.37 to orientate toward and interact with Y2406.51
(Additional file 1: Figure 1S).
H1374.56 is pointed inside the helical bundle in the
rhodopsin and PAR1 -based models, whereas it is more
outside in the crystal structure. As noted by Srivastava
et al. [16] helix 4 in FFA1 has glycine at position 4.58
and does not contain the frequently conserved proline
at position 4.59, providing some flexibility to the upper
part of helix 4, and thus explaining the different pos-
ition of H1374.56.
R1835.39 and L1865.42 are similarly oriented inside the
helical bundle in the modelled and crystal structures but
there is a 4 Å shift in the backbone position of these res-
idues, the result of a more inward position of helix 5 in
the FFA1 crystal structure (Fig. 2). This brings R1835.39ls base on the backbone of the helices in the extracellular side. The crystal
ellow, cyan, pink and grey colour, respectively. Residues predicted to be
622.60, representing the possible anchoring point for allosteric
e the large movement of helices 3, 4 and 5 in the FFA1 crystal
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side chains. None of built homology models had these
interactions.
The network of interactions involving two arginines
and two tyrosines in the FFA1 crystal structure closes
the access to the deeper cavity at FFA1, whereas the ab-
sence of this network of interactions in the homology
models provides a large cavity between helices 3, 4 and 5
(Additional file 1: Figure 1S). This difference has a major
impact on ligand orientation in the modelled and crystal
structures.
In the crystal structure the carboxyl group of TAK-875
forms direct interactions with R1835.39, R2587.35, Y913.37
and Y2406.51 through H-bonding [16] (Fig. 3a). Although
homology modelling in conjunction with mutagenesis
predicted direct interactions with these residues for lino-
leic acid, GW9508 and TAK-875, interactions with
Y913.37 and Y2406.51 were predicted through aromatic
and hydrophobic contacts (Fig. 3b) [13, 14]. The deep
cavity inside the helical bundle (Additional file 1: Figure
1S) in the earlier homology models locks agonists within
the helical bundle allowing the hydrophobic tail of the
ligand to interact with the tyrosines. In this position,
GW9508 was predicted to form aromatic and amino-
aromatic interactions with H1374.56 and hydrophobic in-
teractions with L1865.42 (Fig. 3b). These interactions are
not observed with TAK-875. H1374.56 and L1865.42 are at
the distance of >6 Å from TAK-875 in the crystal struc-
ture. Instead, the hydrophobic part of TAK-875 interacts
with F873.33, F1424.61, W174EL2 and L1384.57 and is
pointed between helices 3 and 4 facing lipids in the ex-
perimental structure (Fig. 3a). This docking position
could not have been predicted in the homology models
as the space between helices 3 and 4 is 2 Å narrowerFig. 3 The ligand binding mode at the FFA1 crystal structure and homolog
in the FFA1 crystal structure, the ligand is pointed between helices 3 and 4 (m
agonist in the previous rhodopsin-based homology model of FFA1. The mod
PAR1-based model of FFA1. Hydrogen bonds are in blackand residues F873.33 and L1384.57 create an obstacle to
the interhelical space. In contrast, docking is to some ex-
tent biased to the cavity formed by helices 4, 5 and 6 as
the hydrophobic moiety of ligands in the crystal struc-
tures of rhodopsin and the β2 receptor is in this location.
Docking to the FFA1 homology model based on the
PAR1 receptor crystal structure predicts a different pos-
ition for the hydrophobic part of an agonist compared to
the rhodopsin- and β2 -based templates. Thus, the
hydrophobic tail of the ligand is between helices 4 and 5
with the possibility of interacting with lipids (Fig. 3c).
This orientation is also similar to the position of the lig-
and in the PAR1 receptor crystal structure. Clearly, the
choice of a template for homology modelling is critical
for establishing the size and shape of the binding cavity
which, in turn, influences ligand docking solutions.
The second extracellular loop (EL2) was challenging to
model due to the absence of any sequence similarity
with the available templates, though modelling has pre-
dicted H-bonding between E172EL2 and R2587.35 cor-
rectly (Fig. 3a) [17]. E145EL2 has been anticipated to be
important in receptor activation by interacting with
R1835.39 in the homology models [17] but has H-bonding
with S178EL2 in the crystal structure (Fig. 3a).
In the crystal structure no water molecules are present
in the TAK-875 binding cavity, however there are water
molecules that are involved in the H-bond network of
interactions with the residues of the FFA1 binding cavity.
A water molecule (HOH2533) forms a water-mediated
hydrogen bond network of interactions with N2446.55,
R2587.53 and S2436.54 (Additional file 2: Figure 2S). The
residue N2446.55 predicted to be important for agonist
binding through hydrogen bonding in the earlier models
contributes to agonist binding indirectly via coordinatingy models. a: the binding model of TAK-875, the ago-allosteric ligand
ode 1 in the text). b: The binding mode of GW9508, the high potency
el was obtained from ref 12. c: The binding mode of TAK-875 in the
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connect EL2 and helices 5 and 7 via interactions with
W174 EL2, E172 EL2, R1835.39 and R2587.53 (Figure 2S).
The site map search predicts the binding cavity within
this area (Additional file 3: Figure 3S).
We noted that K622.60 faces the binding cavity in the
FFA1 crystal structure (Fig. 2), similar to the corre-
sponding residue in the peptide (PAR1, opioid and
CXCR4), lysosphingolipid (S1P1) and nucleotide (P2Y12)
receptor crystal structures, whereas it is at front of the
lipid side in the earlier homology models. The location
of a residue at position 2.60 in the binding site is due to
proline at position 2.58 that causes the kink altering the
packing of neighbouring residues. The role of K622.60, an
additional positively charged residue in the binding
cavity of FFA1 is unknown and mutation of this residue
could be of a great interest to explore its role in ligand
binding. It is tempting to suggest that K622.60 could be
involved in interacting with allosteric modulators, thus
the site map search suggests the binding cavity near
K622.60 (Additional file 3: Figure 3S).
In summary, the low-resolution homology models
were helpful in establishing the location of the ligand
binding site within helices 3, 5, 6 and 7 and the key resi-
dues for ligand anchoring. However, homology models
were not accurate in predicting the nature of all ligand-
receptor contacts and the precise ligand-binding mode.
It appears that the position of helices 3, 4 and 5 affects
docking solutions. It should be noted that the crystal
structure of FFA1 is only available in the complex with
the ago-allosteric ligand, which is assumed to bind in
the overlapping region of the allosteric and orthosteric
binding sites, thus binding of orthosteric agonists could
be distinct from TAK-875 binding.
Ligand docking
Because the crystal structure of FFA1 is available only in
a complex with TAK-875 we next explore docking of a
linoleic acid and synthetic agonists in the experimental
FFA1 structure. Initially, we validate a docking protocol
of the Glide program [20] by re-docking TAK-875 to the
crystal structure to examine whether it can reproduce
the experimental binding pose of TAK-875. In all gener-
ated poses, the Glide standard docking protocol [20] has
reproduced the position of TAK-875 close to the crystal
structure position with a RMSD value of 0.8 Å. Notably,
alanine at position 3.34 in the crystal structure (Fig. 3a)
is a mutation being used together with L42A, G103A
and Y202F to thermostabilise the protein [16]. The ala-
nine is located ~5 Å from TAK-875, whereas phenyl-
alanine at this position in the wild type could be at
distance of 2 Å. Given its potential impact on a ligand
position we rebuilt the wild type of FFA1 and docked
TAK-875 (Fig. 4).The ligand is docked in the similar orientation but with
the higher RMSD of 3 Å, mainly for the biphenyl tail. To
achieve this result, the docking protocol with van der
Waals radius of protein atoms soften from 1 to 0.8 Å was
used. We anticipate that mutation at position 3.34 in the
crystal structure could correct the agonist position. It ap-
pears this change however is not dramatic for the TAK-875
binding affinity [16]. Linoleic acid and GW9508 were
placed similar to TAK-875 in the binding site. The docking
position of GW9508, as an example is shown in Fig. 5a.
To account for flexibility of side chains in the binding
site we use the InducedFit docking protocol [21], where
initial ligand docking is followed by side-chain sampling
and final re-docking into newly-generated receptor con-
formations. Interestingly, we found that TAK-875, linoleic
acid and GW9508 have two binding modes in one of
which the hydrophobic tail of the agonists, similar to the
co-crystalized TAK-875, is pointed in the space between
helices 3 and 4 (Fig. 5a) (mode 1), whereas in another one
the hydrophobic tail of the agonists is pointed in the space
between helices 4 and 5 (mode 2), Fig. 5b. Short simula-
tions of the agonist-receptor complexes show that the li-
gands maintain stably the binding mode obtained in
docking studies. In both modes of binding, the carboxyl
group of ligands forms H-bonding with two arginines and
two tyrosines. In mode 2, GW9508 is able to form aro-
matic and hydrophobic interactions with H1374.56 and
L1865.42 predicted to be important in the earlier homology
models. Thus, Phe and Ala mutations of H1374.56 reduce
the potency of GW9508 by 28- and 100-fold, respectively
[13, 14]. Phe mutation of L1865.42 lowers the potency of
GW9508 by 30-fold [14]. Our docking experiments show
that this binding mode dominates in the FFA1 wild type.
To further explore the induced fit, we conducted con-
formational search of the FFA1 binding site residues of
the crystal structure without a ligand and found the side
chain of F873.33, F1424.61, L1384.57 and W174EL2 residues
closing the interhelical space of helices 3 and 4 in many
generated conformations (Additional file 4: Figure 4S).
Notably, Glide and InducedFit docking to these receptor
conformations gives mode 2 as a favourable solution.
Based on our flexible docking experiments we hypothesize
the possibility of an alternative binding mode for orthos-
teric agonists.
Next, we explored Glide and InducedFit docking of
other agonists - TUG-770 [22], AMG837, AM1638 and
AM8182 [23] of FFA1. TUG-770 is a highly potent
agonist demonstrating profound effects on glucose toler-
ance in mice [22]. AMG837 is a partial agonist, whereas
AM1638 and AM8182 are full agonists; all three appear
to elicit activation through distinct binding sites [23, 24].
Our docking results show different docking preferences.
Mode 1 in Glide docking could be obtained with low en-
ergy only for AMG837 (Additional file 5: Figure 5S). The
Fig. 4 The superimposition of the FFA1 crystal structure and the homology model of the FFA1 wild type bound to TAK-875. The FFA1 wild type model
was constructed from the FFA1 crystal structure using Prime [43]. TAK-875 was docked to the wild type model using Glide [20]. Phenylalanine mutation
at position 3.34 is shown in pink
Tikhonova and Poerio BMC Structural Biology  (2015) 15:16 Page 6 of 13InducedFit docking predicts both modes of binding
with some preference toward mode 2 for AM8182 and
TUG-770 (Additional file 5: Figure 5S). The different
preference in docking modes could provide some struc-
tural insight into a distinct response of AMG837 and
AM8182 to mutation of arginines at positions 5.39 and
7.35 in pharmacological studies [23]. Mode 2 for TUG-
770 could be helpful in interpretation of the SAR studies,
indicating the preference of meta- over ortho- position of
a substituent in the terminal ring. This is because in this
mode the ligand with the meta-group has an extra inter-
action with H1374.56 (Additional file 5: Figure 5S). The
bulky AM1638 compound (Fig. 1) could not be docked
in the specified docking site involving two arginines
and two tyrosines. Indeed AM1638 is unaffected by ar-
ginine mutations [23] in pharmacological assays. We
hypothesise here that AM1638 could bind to the bind-
ing site of the receptor involving K622.60.
To further validate the ligand binding modes at
FFA1, mutagenesis of the residues lining the interhelical
space of helices 3 and 4 as well as helices 4 and 5 will
be beneficial. Thus, the receptor with single or multiplemutations could be constructed, where the replacement
is made to bulky residues or residues with opposite
physicochemical property to prevent binding to one of
the regions. Analysis of such receptor mutants on a
panel of agonists with similar and different chemical
scaffolds as well as pharmacological properties (full ag-
onists, partial agonists, ago-allosteric agonists and
biased agonists) may decipher precise binding modes of
agonists chemically distinct from the co-crystallized
TAK-875.
From docking to the FFA1 crystal structure we predict
the alternative ligand binding mode at the interhelical
space between helices 4 and 5, which could accommo-
date the orthosteric agonists. This binding mode can ex-
plain mutagenesis results for H1374.56 and L1865.42 [13].Free fatty acid receptors 2 and 3
Structural models
The sequence identity of the FFA2 and FFA3 helical
bundle with FFA1 is 32 % and 33 %, respectively, which
is less than the sequence identity between the subtypes
Fig. 5 Two proposed binding modes for the GW9508 agonist in FFA1. a: mode 1, similar to the binding of TAK-875 in the FFA1 crystal structure. b: mode
2, the alternative pose derived from flexible docking. Hydrogen bonds, π- π and π-cation interactions are in black and blue, respectively. The binding site
residues, E145 and E172 of the second extracellular loop predicted to form salt bridges in the earlier models and K622.60 predicted here
to form the allosteric binding site are shown
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(>60 %), suggesting more structural differences between
the FFA receptor subtypes. The sequence identity is
higher between FFA2 and FFA3, 49 %. Sequence align-
ment of the FFA receptors is in Figure 6S (Additional
file 6).
Among other currently available GPCR templates for
homology modeling (Additional files 7 and 8: Figure 7S
and Table 1S), the highest sequence identity of FFA2
and FFA3 within the transmembrane helices is with the
purinergic P2Y12 receptor for FFA2 (30 %) and the PAR1
receptor for FFA3 (33 %). The first models of FFA2 and
FFA3 to study the ligand-receptor interactions were con-
structed using the β2 receptor crystal structure with the
sequence identity of 17 % [10, 25]. We here evaluate the
FFA1-based template in modeling of the FFA2 and FFA3
binding site and ligand-receptor interactions.
Examination of the sequence alignment shows that un-
like FFA1 helices 3 and 4 in FFA2 and FFA3 don’t have
proline and glycine in the upper side, indicating possible
variation of the helix position from FFA1.
Similar to FFA1, residue mutagenesis at FFA2 and
FFA3 shows that the conserved arginines at positions
5.39 and 7.35 and histidine at position 6.55 are im-
portant for coordinating the binding of short chain
fatty acids at FFA2 and FFA3 [26]. Unlike other 25
available templates for homology modelling (Additional
file 7: Figure 7S), the FFA1 template provides a favorable
starting position of the lengthy arginines in the FFA2 andFFA3 homology models for ligand docking. Manual side
chain adjustments to bring the arginine residues together
for the interaction with the carboxyl group of a ligand are
needed when using other templates. Figure 8S (Additional
file 9) shows the superimposition of FFA2 homology
models built using 25 GPCRs with available crystal struc-
tures, with the visualized arginine residues to appreciate
various positions of the arginine side chain. It is therefore
expected that the FFA1-based homology models will be
more suitable for characterizing the FFA2 and FFA3 bind-
ing site compared to the P2Y12 and PAR1 –based hom-
ology models.
Comparison of FFA2 with FFA1 structure reveals a
more intensive network of interactions within the
FFA2 binding site due to extra hydrophilic and aro-
matic residues (Fig. 6, a and b). Thus, Y165EL2 in
FFA2 (L171 in FFA1) and Y903.33 (F87 in FFA1) con-
tribute to aromatic and H-bond networks of interac-
tions with conserved Y943.37, R1805.39, Y2386.51 and
R2557.35. Residue H2426.55 (N244 in FFA1) forms an
H-bond with R2557.53 and aromatic and hydrophobic
interactions with Y943.37 and Y2386.51. In addition,
residues K652.60, E682.63 and E166EL2 contribute to an
H-bonding network within the binding site. The major
difference with the previous FFA2 homology models
[10, 25] is that we didn’t observe this intensive network
of hydrogen bond and aromatic interactions. The higher
quality FFA2 homology model suggests that the binding site
is more packed and less opened from the extracellular side.
Fig. 6 The ligand binding site of the free fatty acid 1–3 receptors a: the binding site in the FFA1 crystal structure; b and c: the binding site in the
FFA1-based homology model of FFA2 and FFA3, respectively. The side chain of the binding site residues in FFAs is shown in blue, pink and green,
respectively. H-bonding, π- π and π-cation interactions are shown in black, blue and green dotted lines, respectively
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accessible in FFA2 compared to FFA1 as it is filled by
residues F873.30 (V84 in FFA1), I1454.61 (F142 in FFA1)
and F1384.54 (L135 in FFA1). In addition, S913.34 (F88 in
FFA1) and C1414.57 (L138 in FFA1) are in very close
proximity to form an H-bond, further closing the hole be-
tween helices. Non-conserved residues such as V1765.35
(A179 in FFA1), V1795.38 (A182 in FFA1) and F168EL2
(W174 in FFA1) also change the entry to the interhelical
space between helices 3 and 4 in FFA2. Overall, the
binding cavity is smaller in FFA2 (332 Å3) than in
FFA1 (400 Å3) (Table 1), providing a geometrical rea-
son to a preference in binding of short (≤C3) over
medium (≥C6) and long chain (≥10) FFAs.
Similar to FFA2, the interhelical space between helices
3 and 4 is less opened in FFA3 due to non-conserved
residues, F933.30 and Y1514.61, filling the interhelical
space (Fig. 6). Compared to FFA1 and FFA2 the H-
bonding network at FFA3 including residues at positions
3.37, 5.39, 6.51 and 7.53 has a different arrangement
likely as a result of the non-conserved residues L171EL2
(GLU in FFA1/FFA2) and PHE at position 3.33 (TYR in
FFA2) that are unable to form H-bonding. Overall,
smaller number of H-bonds is observed in FFA3 com-
pared to FFA2. The binding cavity in FFA3 is larger (385
Å3) compared to FFA2 but smaller than in FFA1
(Table 1). The new models suggest that Y165EL2 in FFA2Table 1 Properties of the binding cavity formed by helices 3–7
Receptor Volume Å3 SASA Å2 SASAphil Å
2
FFA1 400 690 138
FFA2 332 451 208
FFA3 385 455 285
SASA is the solvent accessible surface area of the residues forming the binding cav
hydrophobic, aliphatic or aromatic residues, respectivelyand Y170EL2 in FFA3, which corresponds to L171 EL2 in
FFA1 are located in the center of the FFA orthosteric
site and contributes to reduction of the volume in FFA2
and FFA3, playing likely an important role in subtype se-
lectivity between FFA1 and FFA2-3.
We characterize the physicochemical properties of the
ligand binding sites at FFAs by calculating the solvent
accessible surface area (SASA) of the hydrophilic, hydro-
phobic, aromatic and aliphatic residues of the binding
cavity at FFAs (Table 1). As expected, the SASA of the
hydrophobic residues is significantly higher compared to
the SASA of the hydrophilic residues in all the receptors.
The higher percent of hydrophilicity is in FFA3 (43 %)
compared to FFA2 and FFA1 (30 and 19 %, respectively).
The SASA of aromatic residues has the higher value for
FFA2, 159 Å2, whereas it is 87 and 96 Å2 in FFA1 and
FFA3, respectively. The SASA of aliphatic residues has
the higher value for FFA1, 511 Å2 compared to 309 and
320 Å2 in FFA2 and FFA3, respectively. It appears that
several distinct binding regions within the binding cav-
ities of FFAs could be mapped that were not so clear in
the earlier models.
The EL2 of FFA2 and FFA3 is six- residues shorter
than the EL2 of FFA1. There is some similarity in the
EL2 sequence after the disulfide bridged cysteine. The
EL2 sequence identity is higher between FFA2 and FFA3







ity, SASA with subscript: phil, phob, aliph and arom is SASA of the hydrophilic,
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template for EL2 modeling of FFA2 and FFA3.
Residues L173EL2, Y165EL2 and E166EL2 of FFA2
(Fig. 6b) known to be important for agonist binding
from mutagenesis [25] face the binding cavity in the new
FFA2 model and likely contribute to agonist binding
through a network of interactions with a ligand or resi-
dues of the helices. The residue Q148EL2 (Fig. 6b) gives
substantial loss in the potency of 1 (Fig. 1) in FFA2 when
it is mutated to glutamate and contributes to ligand select-
ivity in the pharmacological studies [25]. The new FFA2
model suggests that Q148EL2 is situated outside of the
binding site and contributes to ligand binding likely indir-
ectly through potential H-bonding with nearby D170EL2
or D174EL2 (Fig. 6b). The glutamate substitution of
Q148EL2 [25] might therefore lead to repulsion and subse-
quent change in the EL2 conformation, which can affect
the ligand binding. D170EL2 and D174EL2 are non-
conserved in FFAs and could be of interest for mutagen-
esis. The conformation of EL2 in FFA2 and FFA3 cannot
suggest a possible ionic salt bridge of G159EEL2 mutation
in FFA2 or D158EL2 in FFA3 (Fig. 6c) with one of the
arginines of the binding site, holding the receptor in the
inactive state, as it was proposed for interpretation of
the reduced constitutive activity of the receptors in
functional essays [27]. These residues are far away from
arginines in the new structural models of the receptors.
It should be noted that the low similarity of the EL2 se-
quence in this region with FFA1 does not allow to
model a precise position and interactions of Q148EL2 in
FFA2 and G159 EL2 in FFA3.
Overall, the new homology models reveal the role of
non-conserved residues in defining a distinct network of
interactions in the ligand binding cavity of FFAs, which
appears to be influential for FFA subtype selectivity.Fig. 7 Ligand binding in FFA2 and FFA3. a: the binding mode of tiglic acid
mode of 1 in FFA2. FFA2-3 homology models are based on the FFA1 cryst
blue dotted lines, respectivelyLigand docking
Docking of the selective short carboxylic acids [10],
FFA2-selective tiglic acid and FFA3-selective 1-MCPC to
the FFA1-based model of FFA2 and FFA3 indicates that
the carboxyl group of the fatty acids is anchored by con-
served R1805.39, R2557.35, Y943.37 and Y2386.51. The non-
conserved residues at positions 5.43 and E166/L171EL2
predicted to be important for FFA2/FFA3 selectivity
together with the residue at position 5.42 in the earlier
homology models contribute more to the shape of the
binding cavity rather than direct interactions with a
ligand (Fig. 7a and b). Instead, the non-conserved resi-
due at position 5.42 is at distance of 4 Å enabling it to
form van der Waals interactions. The hydrophobic part
of the tiglic acid forms hydrophobic contacts with
Y903.33, Y943.37, C1414.57, I1454.61, V1795.38 and Y165EL2
in FFA2, whereas 1-MCPC interacts with F963.33,
L1815.35, V1845.38, R1855.39, M1885.42 and F173EL2 in
FFA3. The new structural models suggest a small bind-
ing cavity in FFA2 due to bulky aromatic residues and
an intensive H-bonding network, structurally explaining
a preference in binding of carboxylic acids with sp2
hybridized α-carbons to FFA2, whereas a larger binding
cavity in FFA3 with a lesser network of interactions
could be a reason for a preference in binding of carbox-
ylic acids with sp3 hybridized α-carbons to FFA3 as ob-
served in pharmacological studies [10]. We predict that
the residues that determine subtype selectivity between
FFA2 and FFA3 are Y903.33, I1454.61 and E166EL2 in
FFA2 and the corresponded F963.33, Y1514.61 and
L171EL2 in FFA3.
In addition, we have docked 1, a highly potent synthetic
agonist to the FFA1-based model of FFA2 to compare
with the earlier ligand binding mode predicted from the
β2-receptor-based homology model and mutagenesis [25].at FFA2. b: the binding mode of 1-MCPC in FFA3. c: the binding
al structure. H-bonding and π- π interactions are shown in black and
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FFA2 model in a similar fashion. In particular, the carb-
oxyl group of the ligand contributes to a network of inter-
actions through H-bonding involving Y903.33, Y943.37,
R1805.39, Y2386.51, H2426.55 and R2557.35 (Fig. 7c), similar
to TAK-875 binding in the crystal structure of FFA1 and
different from earlier predictions, where tyrosines had
hydrophobic interactions with 1. The aromatic moiety of
the agonist is pointed between helices 4 and 5 forming
aromatic interactions with H1404.56 and hydrophobic con-
tacts with V1795.38 and L1835.42. Similar to FFA1, histidine
at position 4.56 has some notable effect on the activity of
fatty acids in FFA2 and FFA3 [26, 28] and greatly reduces
the activity of 1, a highly potent synthetic agonist in FFA2
[25]. This orientation is different from the position of the
TAK-875 hydrophobic tail but similar to predicted agonist
binding mode 2 in FFA1. The cyclopropyl group of 1
forms hydrophobic interactions with V1765.35, V1795.38
and R1805.39, and the cyclopentyl group makes contacts
with C1414.57, V1444.60, I1454.61 and F168EL2. The import-
ance of residues at positions 3.33, 4.56, 5.38, 5.39, 6.51,
6.55 and 7.35 in binding of 1 is supported by mutagenesis
[25]. The new model suggests the residues at positions
3.37, 4.60, 4.57, 5.35 and F168EL2 are now involved in dir-
ect interactions with 1.
Allosteric agonists, AMG7703 [12, 29] of FFA2 and
2 of FFA3 [30] (Fig. 1) have been recently identified.
Alanine mutation of arginines at positions 5.39 and
7.35 does not affect the binding of these ligands in
the corresponding receptors, indicating that a binding
site of these ligands is distinct from free fatty acids
[30, 31]. Several residues of the FFA2 receptor extra-
cellular cavity predicted based on the β2 homology
model have been mutated to identify the binding site
of AMG7703 but none of the mutations substantially
affected the potency of AMG7703 [28, 31]. It has been
only shown experimentally that the allosteric property of
AMG7703 is prevented by the L173AEL2 mutant or substi-
tution of EL2 with that of FFA3 [31]. In the new FFA2
model, L173EL2 faces the binding cavity and links the EL2
loop with helix 6, potentially involved in the ligand bind-
ing process and subsequent conformational changes lead-
ing to activation. Similar to FFA1 allosteric ligands, we
hypothesize that the extracellular side involving helices 1,
2 and 7 with the positively charged residue at position
2.60 (LYS in FFA2 and ARG in FFA3) could form the allo-
steric binding site in FFA2 and FFA3 (Additional file 3:
Figure 3S).
In summary, the novel FFA2 and FFA3 models further
delineate the orthosteric agonist binding site by inter-
preting the few available mutagenesis data. Importantly,
the novel models highlight non-conserved residues lining
the orthosteric binding site at FFA2 and FFA3 that could
be used for further mutagenesis studies. Interestingly,unlike FFA1, the FFA2 agonists cannot be easily docked to
the interhelical space between helices 3 and 4, however we
cannot exclude this option. Similar to FFA1, mutagenesis
of residues in helices 3, 4 and 5 and binding studies with
different agonists would help in establishing ligand bind-
ing modes at FFA2. The higher quality homology models
could be now probed in in silico structure-based design,
helping to discover the first FFA3 orthosteric ligands.
Finally, novel models suggest the location of the allosteric
agonist binding site.
Conclusions
The free fatty acid receptors are recently discovered G
protein-coupled receptors with potential impact to im-
prove the life of patients suffering from diabetes, obesity
and immune diseases. However, the absence of a large
pool of various small molecule modulators with high
potency and selectivity as well as acceptable pharmaco-
kinetic properties create an obstacle to characterize FFA
biology and physiology and subsequent validate these
drug targets in the clinics. The published crystal struc-
ture of FFA1 in the complex with TAK-875 in the last
year [16] represents the first direct structural knowledge
of binding at the FFA1 receptor and facilitates the ex-
ploration of the binding sites at FFA2 and FFA3.
Our comparison of the previous models and the
crystal structure of the FFA1 receptor shows that the
homology models based on templates with 16–18 %
sequence identity were useful in locating the binding
site at FFAs and identifying key residues for binding
but not accurate in establishing the precise network
of ligand-protein interactions and the ligand binding
mode. Furthermore, modelling of EL2 is a challenging
task to complete and this challenge still remains for
FFA2 and FFA3 as there is low sequence similarity
with FFA1. Our findings are in the line with conclusions
made from community-based assessments of GPCR mod-
elling on the example of the adenosine A2A, dopamine D3,
chemokine CXCR4, serotonin 5HT1B and 5HT2B and
smoothened receptors [32–34].
From modelling of the FFA1 receptor we posit that
when the sequence identity is low (<20 %) with respect
to the receptors with available crystal structures, it is
useful to explore several templates for homology model-
ling. Thus, crystal structures of templates with differing
positions of a ligand in the binding cavity can help to
examine various ligand binding modes in docking stud-
ies. Care should be taken with helices containing proline
and glycine as these residues can remarkably change side
chain packing and vary the position of the extracellular
tips of the helices creating a distinct shape and size of
the binding cavity, thus affecting docking conditions.
Furthermore, multiple templates could help in exploring
various orientations of the side chain of lengthy residues
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FFA modelling was to predict a favourable position of
the arginines for ligand docking. The importance of
multiple templates for GPCR modelling has been dis-
cussed in literature using other receptors as a case study
[35, 36].
Docking to the FFA1 crystal structure predicts an al-
ternative binding mode for agonists, in which the ligand
hydrophobic tail is at the interhelical space between
helices 4 and 5. A similar mode of binding is predicted
for FFA2 agonists. This binding mode can be linked
with the available mutagenesis data. The FFA1-based
models of FFA2 and FFA3 suggest hydrogen bonding of
the agonist carboxyl group with two tyrosines at posi-
tions 3.37 and 6.51, in addition to two anchoring argi-
nines. Overall, the new structural models of FFAs give
more details on molecular reasons for the preference in
binding of long or short chain fatty acids by highlighting
the difference in the network of interactions between the
receptors and identifying the position of non-conserved
residues, which contribute to the shape and volume of the
binding sites. In particular, we predict residues at positions
3.33, 4.61, 6.55 and two residues followed the disulfide
bridged cysteine in the second extracellular loop play a
central role in FFA subtype selectivity.
Novel structural models of FFAs suggest the location
of an allosteric binding site. Thus, the cavity between
helices 2 and 7 and EL2 with a putatively anchoring role
of the residue at position 2.60 is predicted. This residue
has not been appreciated in earlier homology models as
it was pointed outside of the helical bundle. To validate
the importance of this residue in binding of allosteric
modulators will require mutagenesis experiments. Inter-
estingly, this positively-charged residue in helix 2 makes
the FFAs binding cavity somewhat similar with the FFA4
(GPR120) receptor – the receptor with a preference in
binding of the long chain fatty acids, which has the
positive-charged residue at position 2.64 coordinating
the carboxyl group of agonists [37, 38]. Despite binding
the long chain fatty acids like FFA1, this receptor has
substantially low sequence identity with FFAs (<19 %).
FFA structural models provide more details on receptor-
agonist interactions and suggest novel predictions for muta-
genesis and medicinal chemistry. Further insights in ligand
binding modes at FFAs will be fuelled by availability of re-
ceptor mutagenesis data for various ligands, including
orthosteric and allosteric agonists and antagonists in the
short term and validated by new crystal structures of FFAs
bound to different ligands in the long term.
Methods
Homology modelling
The FFA1 crystal structure with the PDB code of 4PHU
was used for ligand docking and homology modelling ofFFA2-3. Homology models were also built based on the
crystal structures with PDB code of 1U19, 3CAP, 3PBL,
3RZE, 2RH1, 4AMJ, 3V2Y, 4EIY, 3ODU, 4DAJ, 3UON,
4DJH, 4DKL, 4EJ4, 4EA3, 3VW7, 4GRV, 4IAR, 4IB4,
4MBS and 4NTJ to compare with the FFA1 crystal
structure and produce Figure 8S. The sequence align-
ment strategy for the GPCR family is described by
Costanzi [39] is used in this work. Briefly, multiple
sequence alignment was built using CLUSTALW [40]
with the BLOSUM62 matrix [41] for helices. Subse-
quent visual inspection of the alignment and manual
adjustment was performed to match the helix conserved
motifs of GPCRs: GX3N for helix 1, N(S,H)LX3DX7,8,9P
for helix 2, SX3LX2IX2D(E,H)RY for helix 3, WX8,9P for
helix 4, FX2PX7Y for helix 5, FX2CW(Y,F)XP for helix 6
and LX3NX3N(D)PX2YX5,6F for helices 7 and 8, where Xn
is n neighbouring non-conserved residues and residues in
parentheses substitute the preceding residue. Due to the
low sequence similarity and length variability of the loops,
the alignment is performed in a pairwise manner compar-
ing the target receptor with a template receptor. In the
case of the FFAs family, all the three members of the fam-
ily were aligned for the loop alignment (Additional file 6:
Figure 6S). The sequence alignment between FFA1-3 and
25 GPCRs with the available crystal structures (Additional
file 7: Figure 7S) was also verified using the HHpred server
[42], which uses the pairwise comparison of profile hidden
Markov models. This server has predicted correctly all the
transmembrane helices and identified the conserved mo-
tifs. Unlike the BLOSUM-based alignment no manual
refinements are need to be made for loop regions. The
probability, E-values and p-values (Additional file 7:
Table 2S) from HHpred server show high reliability of
the alignment. The homology models were generated
with Prime 3.8 [43] using the default settings. The models
were refined using a default energy minimization protocol
implemented in Prime 3.8.
Molecular docking
The FFA1 crystal structure was prepared with the pro-
tein preparation utility of Maestro 9.9 [44]. Molecular
docking to FFA1-3 was conducted using Glide 6.5 [45].
The receptor grid was defined by selecting residues
at positions 3.37, 4.57, 5.39, 6.51 and 7.35. The
standard precision (XP) Glide protocol without any
constraints was used for docking. The InducedFit
protocol [20, 21, 43, 45, 46] with the docking box de-
fined using the residues above was used and no side chain
trimming was applied in a re-docking part of the protocol.
For FFA2, the side chain trimming was applied for Y165
and Y149 that widely occluded the binding cavity. The
best scored binding pose of TAK-875 was compared to
the co-crystallized orientation of TAK-875 and the RMSD
was calculated as a measure of docking reliability. For the
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was chosen based on the docking energy and agreement
with residue mutagenesis data and ligand structure-
activity relationship (SAR) data.
Analysis of structural models
To investigate the water-mediated interactions, hydro-
gens are added and minimized using a standard protocol
of the protein preparation utility of Maestro 9.9. For the
SASA and volume calculations residues: P80, V81, A83,
V84, F87, F88, L90, Y91, L135, L138, F142, V141, L158,
A179, A182, R183, N244, Y240, R258, L171, W174,
G143, G139 and E172 in FFA1 and the residues at the
same positions in FFA2 and FFA3 were selected. The
SASA and volume was calculated with VMD 1.9.2beta1
[47] and Chimera 1.6 [48], respectively. SiteMap 3.3 [49]
with the minimal 9 site points was used to predict bind-
ing sites. The 500 ps molecular dynamics simulations
were conducted to examine the stability of the ligand
binding modes using MacroModel 9.9 [50]. OPLS_2005
force fields were used and the surface area-based version
of the generalized Born model (GB/SA) were used for
treatment of solvent and its dielectric constant was
assigned a value of 1. Conformational search for FFA1 in
the ligand-free form were performed using the Monte
Carlo multiple minimum method as implemented in
MacroModel 9.9 [50]. Residues located within 5 Å of
GW9508 in modes 1 and 2 were subjected to extend tor-
sional sampling. A shell of frozen atoms within 4 Å was
also included in the conformational search, whereas the
remaining atoms were excluded. 5000 steps of the
Monte Carlo multiple minimum method were per-
formed, and the resulting structures were saved with a
potential energy lower than 100 kJ/mol. Figures of the
molecular models were generated with Maestro 9.9 [44].
Endnote
a The number in superscript is the Ballesteros-
Weinstein indexing system [51], where the most con-
served residue in a given helix is assigned the index
X.50 with X as the helix number, while the remaining
residues are numbered relatively to position 50.
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